206 related articles for article (PubMed ID: 37834346)
21. LINE-1: an emerging initiator of cGAS-STING signalling and inflammation that is dysregulated in disease.
Mathavarajah S; Dellaire G
Biochem Cell Biol; 2024 Feb; 102(1):38-46. PubMed ID: 37643478
[TBL] [Abstract][Full Text] [Related]
22. An ATR- and BRCA1-mediated Fanconi anemia pathway is required for activating the G2/M checkpoint and DNA damage repair upon rereplication.
Zhu W; Dutta A
Mol Cell Biol; 2006 Jun; 26(12):4601-11. PubMed ID: 16738325
[TBL] [Abstract][Full Text] [Related]
23. Therapeutic Targeting of the DNA Damage Response Using an ATR Inhibitor in Biliary Tract Cancer.
Nam AR; Jin MH; Park JE; Bang JH; Oh DY; Bang YJ
Cancer Res Treat; 2019 Jul; 51(3):1167-1179. PubMed ID: 30514066
[TBL] [Abstract][Full Text] [Related]
24. Upregulated ATM gene expression and activated DNA crosslink-induced damage response checkpoint in Fanconi anemia: implications for carcinogenesis.
Yamamoto K; Nihrane A; Aglipay J; Sironi J; Arkin S; Lipton JM; Ouchi T; Liu JM
Mol Med; 2008; 14(3-4):167-74. PubMed ID: 18224251
[TBL] [Abstract][Full Text] [Related]
25. cGAS Regulates the Radioresistance of Human Head and Neck Squamous Cell Carcinoma Cells.
Nyui T; Yoshino H; Nunota T; Sato Y; Tsuruga E
Cells; 2022 Apr; 11(9):. PubMed ID: 35563740
[TBL] [Abstract][Full Text] [Related]
26. Targeting DNA damage response components induces enhanced STING-dependent type-I IFN response in ATM deficient cancer cells and drives dendritic cell activation.
Lopez-Pelaez M; Young L; Vazquez-Chantada M; Nelson N; Durant S; Wilkinson RW; Poon E; Gaspar M; Valge-Archer V; Smith P; Dovedi SJ
Oncoimmunology; 2022; 11(1):2117321. PubMed ID: 36117525
[TBL] [Abstract][Full Text] [Related]
27. CRL4 ubiquitin ligase stimulates Fanconi anemia pathway-induced single-stranded DNA-RPA signaling.
Codilupi T; Taube D; Naegeli H
BMC Cancer; 2019 Nov; 19(1):1042. PubMed ID: 31690264
[TBL] [Abstract][Full Text] [Related]
28. Functional analyses of ATM, ATR and Fanconi anemia proteins in lung carcinoma : ATM, ATR and FA in lung carcinoma.
Beumer JH; Fu KY; Anyang BN; Siegfried JM; Bakkenist CJ
BMC Cancer; 2015 Oct; 15():649. PubMed ID: 26438152
[TBL] [Abstract][Full Text] [Related]
29. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
30. Hsp90 inhibitor-mediated disruption of chaperone association of ATR with hsp90 sensitizes cancer cells to DNA damage.
Ha K; Fiskus W; Rao R; Balusu R; Venkannagari S; Nalabothula NR; Bhalla KN
Mol Cancer Ther; 2011 Jul; 10(7):1194-206. PubMed ID: 21566061
[TBL] [Abstract][Full Text] [Related]
31. SETD2 Loss and ATR Inhibition Synergize to Promote cGAS Signaling and Immunotherapy Response in Renal Cell Carcinoma.
Liu XD; Zhang YT; McGrail DJ; Zhang X; Lam T; Hoang A; Hasanov E; Manyam G; Peterson CB; Zhu H; Kumar SV; Akbani R; Pilie PG; Tannir NM; Peng G; Jonasch E
Clin Cancer Res; 2023 Oct; 29(19):4002-4015. PubMed ID: 37527013
[TBL] [Abstract][Full Text] [Related]
32. Acquisition of Relative Interstrand Crosslinker Resistance and PARP Inhibitor Sensitivity in Fanconi Anemia Head and Neck Cancers.
Lombardi AJ; Hoskins EE; Foglesong GD; Wikenheiser-Brokamp KA; Wiesmüller L; Hanenberg H; Andreassen PR; Jacobs AJ; Olson SB; Keeble WW; Hays LE; Wells SI
Clin Cancer Res; 2015 Apr; 21(8):1962-72. PubMed ID: 25609062
[TBL] [Abstract][Full Text] [Related]
33. Targeting ATR Pathway in Solid Tumors: Evidence of Improving Therapeutic Outcomes.
Mavroeidi D; Georganta A; Panagiotou E; Syrigos K; Souliotis VL
Int J Mol Sci; 2024 Feb; 25(5):. PubMed ID: 38474014
[TBL] [Abstract][Full Text] [Related]
34. Mutated
Bertola N; Degan P; Cappelli E; Ravera S
Cells; 2022 Jul; 11(15):. PubMed ID: 35954197
[TBL] [Abstract][Full Text] [Related]
35. Dissecting cellular responses to irradiation via targeted disruptions of the ATM-CHK1-PP2A circuit.
Palii SS; Cui Y; Innes CL; Paules RS
Cell Cycle; 2013 Apr; 12(7):1105-18. PubMed ID: 23462183
[TBL] [Abstract][Full Text] [Related]
36. Exploring the ATR-CHK1 pathway in the response of doxorubicin-induced DNA damages in acute lymphoblastic leukemia cells.
Ghelli Luserna Di Rorà A; Ghetti M; Ledda L; Ferrari A; Bocconcelli M; Padella A; Napolitano R; Fontana MC; Liverani C; Imbrogno E; Bochicchio MT; Paganelli M; Robustelli V; Sanogo S; Cerchione C; Fumagalli M; Rondoni M; Imovilli A; Musuraca G; Martinelli G; Simonetti G
Cell Biol Toxicol; 2023 Jun; 39(3):795-811. PubMed ID: 34519926
[TBL] [Abstract][Full Text] [Related]
37. Gefitinib and Afatinib Show Potential Efficacy for Fanconi Anemia-Related Head and Neck Cancer.
Montanuy H; Martínez-Barriocanal Á; Antonio Casado J; Rovirosa L; Ramírez MJ; Nieto R; Carrascoso-Rubio C; Riera P; González A; Lerma E; Lasa A; Carreras-Puigvert J; Helleday T; Bueren JA; Arango D; Minguillón J; Surrallés J
Clin Cancer Res; 2020 Jun; 26(12):3044-3057. PubMed ID: 32005748
[TBL] [Abstract][Full Text] [Related]
38. Fanconi anemia-isogenic head and neck cancer cell line pairs: A basic and translational science resource.
Nguyen HT; Tang W; Webster ALH; Whiteaker JR; Chandler CM; Errazquin R; Roohollahi K; Fritzke M; Hoskins EE; Jonlin E; Wakefield L; Sullivan LB; Chen EY; Dorsman J; Brakenhoff R; Paulovich AG; Grompe M; Garcia-Escudero R; Wells SI; Smogorzewska A; Monnat RJ
Int J Cancer; 2023 Jul; 153(1):183-196. PubMed ID: 36912284
[TBL] [Abstract][Full Text] [Related]
39. Defects in the Fanconi Anemia Pathway and Chromatid Cohesion in Head and Neck Cancer.
Stoepker C; Ameziane N; van der Lelij P; Kooi IE; Oostra AB; Rooimans MA; van Mil SE; Brink A; Dietrich R; Balk JA; Ylstra B; Joenje H; Feller SM; Brakenhoff RH
Cancer Res; 2015 Sep; 75(17):3543-53. PubMed ID: 26122845
[TBL] [Abstract][Full Text] [Related]
40. Cisplatin resistance in non-small cell lung cancer cells is associated with an abrogation of cisplatin-induced G2/M cell cycle arrest.
Sarin N; Engel F; Kalayda GV; Mannewitz M; Cinatl J; Rothweiler F; Michaelis M; Saafan H; Ritter CA; Jaehde U; Frötschl R
PLoS One; 2017; 12(7):e0181081. PubMed ID: 28746345
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
